Warner Chilcott (NASDAQ:WCRX) reported Q1 EPS of $1.16, topping estimates of $0.17. Revenues in the quarter fell 9.5% year-over-year to $685 million, missing estimates by $37 million. Warner Chilcott sees FY 2012 adjusted CNI per share $3.30-$3.40, vs. its prior guidance of $3.60-$3.70. The company sees revenues of $2.4 billion – $2.5 billion, vs. its prior guidance of $2.5 billion – $2.6 billion. SmarTrend is bullish on shares of Warner Chilcott and our subscribers were alerted to buy on April 25, 2012 at $17.30. The stock has risen 25.1% since the alert was issued. Warner Chilcott PLC is a pharmaceutical company. The Company is focused on marketing, selling, developing and manufacturing branded prescription pharmaceutical products in women’s healthcare and dermatology in the United States.
